Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations

American Journal of the Medical Sciences

Volumn 339, Issue 1, 2010, Pages 1-4

  McKinzie, Brian P ^a   Bullington, Wendy M ^a   Mazur, Joseph E ^a   Judson, Marc A ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Corticosteroids; Exacerbation; Low dose; Sarcoidosis

Indexed keywords

PREDNISONE;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CORTICOSTEROID THERAPY; DATA BASE; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GENERAL CONDITION IMPROVEMENT; HUMAN; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; SARCOIDOSIS; SHORT COURSE THERAPY; SPIROMETRY; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 75449095453     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181b97635     Document Type: Article

References (19)

1. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997;111: 623-631
2. Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 1998;15:52-58
3. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A case control etiologic study of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:75-86.
4. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis 1971;103:57-67.
5. Knudson RJ, Slatin R, Lebowitz MD, et al. The maximal expiratory flow-volume curve. Am Rev Respir Dis 1976;113:587-600.
6. Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994;149:893-898
7. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996;51:238-247
8. Harkleroad LE, Young RL, Savage PJ, et al. Pulmonary sarcoidosis. Long-term follow-up of the effects of steroid therapy. Chest 1982;82: 84-87
9. Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973;107:609-614
10. Eule H, Weinecke A, Roth I, et al. The possible influence of corticosteroid therapy on the natural course of pulmonary sarcoidosis. Late results of a continuing clinical study. Ann N Y Acad Sci 1986;465: 695-701.
11. Zaki MH, Lyons HA, Leilop L, et al. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. N Y State J Med 1987;87:496-499
12. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002;287:1301-1307
13. Pietinalho A, Tukiainen P, Haahtela T, et al. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Chest 1999;116:424-431
14. Pietinalho A, Tukiainen P, Haahtela T, et al; Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002;121:24-31.
15. Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J 1995;8:682-688
16. Young RL, Harkleroad LE, Lordon RE, et al. Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy. Ann Intern Med 1970;73:207-212
17. Yamamoto M, Saito N, Tachibana T, et al. Effects of 18 month corticosteroid therapy on stage I and stage II sarcoidosis patients. 9th International Conference on Sarcoidosis. Oxford: Pergamon; 1983. p. 470-474
18. Johns CJ, Schonfeld SA, Scott PP, et al. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann N Y Acad Sci 1986;465:702-712
19. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:149-173 (Pubitemid 29469097)